BPC-157
A 15-amino-acid peptide with strong preclinical evidence for soft-tissue and gut repair.
What it is
BPC-157 (Body Protective Compound-157) is a synthetic 15-amino-acid peptide derived from a partial sequence of a larger gastric protective protein originally isolated from human gastric juice in the 1990s by Predrag Sikiric and colleagues at the University of Zagreb. The name reflects its hypothesized biological role as a body-wide protective signaling molecule. Its full peptide sequence is GEPPPGKPADDAGLV.
BPC-157 has not received FDA approval for any indication, but it has accumulated an unusually large preclinical literature — more than 200 published animal studies — exploring its effects across a wide range of injury models. In the US it is available through licensed compounding pharmacies. The WADA (World Anti-Doping Agency) has placed BPC-157 on its prohibited list for athletes since 2022.
Stability is one of BPC-157’s notable properties: unlike most peptides, it remains stable in human gastric juice for over 24 hours, which makes oral administration a viable route for some indications.
Mechanism of action
BPC-157’s mechanism appears genuinely multi-modal, which has been a source of both interest and skepticism. Documented effects in preclinical models include:
- Angiogenesis: upregulation of vascular endothelial growth factor (VEGF) and its receptor VEGFR2, promoting formation of new blood vessels in injured tissue. Multiple studies show enhanced microvascular network formation around wounds and injured tendons.
- Nitric oxide system modulation: BPC-157 interacts with the nitric oxide signaling system in ways that protect endothelium and modulate vascular tone. It can reverse some pathological effects of NOS blockade in animal models.
- Growth factor expression: increased expression of growth hormone receptor on tendon fibroblasts, potentially explaining tissue-specific responsiveness in tendon repair.
- Gastric mucosal protection: the original observation that led to the peptide’s isolation. BPC-157 protects gastric mucosa against various insults including NSAIDs, alcohol, and acid.
- Dopaminergic and serotonergic effects: modulation of these neurotransmitter systems has been documented, with some neuroprotective effects in animal models of CNS injury.
The diversity of mechanisms is mechanistically interesting but has also raised legitimate skepticism — peptides with very narrow receptor specificity are usually easier to characterize than ones reported to do many different things.
Research findings
The asymmetry between preclinical and human evidence is BPC-157’s defining feature. We are honest with patients about this.
Preclinical evidence (extensive): hundreds of animal studies showing benefit across tendon and ligament injury models, gastric ulceration, inflammatory bowel disease, traumatic brain injury, fracture healing, diabetic wound healing, and ischemia-reperfusion injury. Consistent themes: enhanced healing time, improved tensile strength of repaired tissues, reduced inflammation, and protective effects against tissue insults. The work is concentrated in the Sikiric laboratory and collaborating groups but has been replicated by independent investigators.
Human evidence (limited): No large randomized controlled trials in humans exist. A small Phase I study established basic pharmacokinetics. Practitioner observational data and case series support benefits in tendinopathy and post-surgical recovery, but this is exactly the kind of evidence base that requires healthy skepticism.
Why the gap exists: BPC-157 is not patent-protected as a novel composition (it’s a fragment of a naturally occurring protein), reducing pharmaceutical industry incentive to fund the multi-hundred-million-dollar trials needed for FDA approval. The peptide remains in a category where preclinical promise has not yet been matched by Western RCT validation.
How we use it at The Tide
BPC-157 is among our most-prescribed peptides, used selectively for indications where the preclinical evidence aligns with patient need and where conservative care has been insufficient.
Primary indications we use it for:
- Chronic tendinopathy that has not responded to physical therapy, eccentric loading, and time
- Post-surgical soft-tissue recovery, with the patient’s surgeon’s knowledge
- Gut barrier protocols including suspected leaky gut, IBD-adjacent symptoms, and post-NSAID gastritis (oral administration)
- Ligament sprains and minor tears in the recovery phase
- Generalized inflammatory states where multiple body systems are affected and standard care has plateaued
Standard dosing: 250–500 mcg subcutaneously near the affected area (or in the abdomen for systemic effect), once or twice daily, for 4–6 weeks. For gut indications, oral administration at 500 mcg twice daily is often preferred. We typically do not exceed 8 weeks in a single cycle and recommend a break of equal length between cycles.
What good response looks like: patients with tendinopathy often report 30–50% pain reduction by week 3 and meaningful functional improvement by week 6. Gut symptoms typically improve within 2–4 weeks of oral therapy. Patients who see no benefit by week 4 are unlikely to benefit from extended cycles.
Side effects and contraindications
BPC-157 has been remarkably well-tolerated across decades of clinical use. The most common report is mild irritation at the injection site. Significant systemic side effects are rare in the published preclinical record and in clinical experience.
Theoretical concerns we take seriously:
- Angiogenesis and malignancy: any agent that promotes new blood vessel formation could theoretically support tumor vascularization. We screen carefully for active or recent malignancy before prescribing and avoid use in patients with undiagnosed lumps, abnormal imaging, or other concerning features.
- Pregnancy and breastfeeding: we do not prescribe in these populations given the absence of dedicated safety data.
- Long-term continuous use: the safety profile in published studies is short-term (weeks to a few months). We do not recommend continuous indefinite use.
What we don’t yet know
The most fundamental gap is the absence of large human RCTs validating any specific clinical indication. Optimal dose, optimal route (oral vs. subcutaneous vs. local injection at injury site), and optimal cycle length are all empirical. Long-term safety beyond several months of continuous use is not well characterized. The mechanism of tissue specificity — why BPC-157 appears to act selectively on injured tissue rather than producing diffuse effects — is interesting but not fully explained. Patients deserve honesty about this evidence landscape: BPC-157 is one of the more promising compounds in our toolkit, but it is not a proven pharmaceutical.